Julia T. Warren

Julia T. Warren

Auto-generated profile, based on publicly available information

Julia T. Warren

Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 August 2009 in The EMBO Journal
Verified
Journal Article
Closed access
MCMickaël V Cherrier
Mickaël V Cherrier
BKBärbel Kaufmann
Bärbel Kaufmann
GNGrant E Nybakken
Grant E Nybakken
SLShee‐Mei Lok
Shee‐Mei Lok
JWJulia T Warren
Julia T Warren
DFDaved H Fremont
Daved H Fremont

1 November 2012 in Structure
Verified
Journal Article
Closed access
CNChristopher A. Nelson
Christopher A. Nelson
JWJulia T. Warren
Julia T. Warren
MWMichael W.-H. Wang
Michael W.-H. Wang
STSteven L. Teitelbaum
Steven L. Teitelbaum
DFDaved H. Fremont
Daved H. Fremont

17 April 2012 in Journal of Cellular Biochemistry
Verified
Journal Article
Closed access
PDF file
Carl DeSelmCarl DeSelm
Carl DeSelm
YTYoshifumi Takahata
Yoshifumi Takahata
JWJulia Warren
Julia Warren
JCJean C. Chappel
Jean C. Chappel
TKTaimur Khan
Taimur Khan
STSteven L. Teitelbaum
Steven L. Teitelbaum

31 July 2020 in Blood
Verified
Journal Article
Open access
PDF file
JWJulia T. Warren
Julia T. Warren
DLDaniel C. Link
Daniel C. Link
Clonal hematopoiesis is common in older persons and is associated with an increased risk of hematologic cancer. Here, we review studies establishing an association between clonal hematopoiesis and hematopoietic malignancy, discuss features of clonal hematopoiesis that are predictive of leukemic progression, and explore the role of hematopoietic stressors in the evolution of clonal hematopoiesis to acute myeloid leukemia or myelodysplastic syndrome. Clonal hematopoiesis due to point mutations or structural variants, such as copy number alterations, are associated with an approximately 10-fold increased risk of hematopoietic malignancy. Although the absolute risk of hematopoietic malignancy is low, certain features of clonal hematopoiesis may confer a higher risk of transformation, including the presence of TP53 or splicesome gene mutations, a variant allele fraction greater than 10%, the presence of multiple mutations, and altered red blood indices. Clonal hematopoiesis in the setting of peripheral blood cytopenias carries a very high risk of progression to a myeloid malignancy and merits close observation. There is emerging evidence to suggest the hematopoietic stressors contribute both to the development of clonal hematopoiesis and progression to hematopoietic malignancy. Specifically, there is evidence that genotoxic stress from chemotherapy or radiation therapy, ribosome biogenesis stress, and possibly inflammation may increase the risk of transformation from clonal hematopoiesis to a myeloid malignancy. Models that incorporate features of clonal hematopoiesis along with an assessment of hematopoietic stressors may eventually help predict and prevent the development of hematopoietic malignancies.

3 February 2022 in Blood
Verified
Journal Article
Open access
PDF file
JWJulia T. Warren
Julia T. Warren
RCRyan R. Cupo
Ryan R. Cupo
PWPeeradol Wattanasirakul
Peeradol Wattanasirakul
DSDavid H. Spencer
David H. Spencer
ALAdam E. Locke
Adam E. Locke
DLDaniel C. Link
Daniel C. Link
Severe congenital neutropenia is an inborn disorder of granulopoiesis. Approximately one third of cases do not have a known genetic cause. Exome sequencing of 104 persons with congenital neutropenia identified heterozygous missense variants of CLPB (caseinolytic peptidase B) in 5 severe congenital neutropenia cases, with 5 more cases identified through additional sequencing efforts or clinical sequencing. CLPB encodes an adenosine triphosphatase that is implicated in protein folding and mitochondrial function. Prior studies showed that biallelic mutations of CLPB are associated with a syndrome of 3-methylglutaconic aciduria, cataracts, neurologic disease, and variable neutropenia. However, 3-methylglutaconic aciduria was not observed and, other than neutropenia, these clinical features were uncommon in our series. Moreover, the CLPB variants are distinct, consisting of heterozygous variants that cluster near the adenosine triphosphate-binding pocket. Both genetic loss of CLPB and expression of CLPB variants result in impaired granulocytic differentiation of human hematopoietic progenitor cells and increased apoptosis. These CLPB variants associate with wild-type CLPB and inhibit its adenosine triphosphatase and disaggregase activity in a dominant-negative fashion. Finally, expression of CLPB variants is associated with impaired mitochondrial function but does not render cells more sensitive to endoplasmic reticulum stress. Together, these data show that heterozygous CLPB variants are a new and relatively common cause of congenital neutropenia and should be considered in the evaluation of patients with congenital neutropenia.

1 May 2014 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
TFTomohiro Fukunaga
Tomohiro Fukunaga
WZWei Zou
Wei Zou
JWJulia T. Warren
Julia T. Warren
STSteven L. Teitelbaum
Steven L. Teitelbaum
Osteoclastic bone resorption depends upon the cell's ability to organize its cytoskeleton. Because vinculin (VCL) is an actin-binding protein, we asked whether it participates in skeletal degradation. Thus, we mated VCLfl/fl mice with those expressing cathepsin K-Cre (CtsK-VCL) to delete the gene in mature osteoclasts or lysozyme M-Cre (LysM-VCL) to target all osteoclast lineage cells. VCL-deficient osteoclasts differentiate normally but, reflecting cytoskeletal disorganization, form small actin rings and fail to effectively resorb bone. In keeping with inhibited resorptive function, CtsK-VCL and LysM-VCL mice exhibit a doubling of bone mass. Despite cytoskeletal disorganization, the capacity of VCL−/− osteoclastic cells to normally phosphorylate c-Src in response to αvβ3 integrin ligand is intact. Thus, integrin-activated signals are unrelated to the means by which VCL organizes the osteoclast cytoskeleton. WT VCL completely rescues actin ring formation and bone resorption, as does VCLP878A, which is incapable of interacting with Arp2/3. As expected, deletion of the VCL tail domain (VCL1–880), which binds actin, does not normalize VCL−/− osteoclasts. The same is true regarding VCLI997A, which also prevents VCL/actin binding, and VCLA50I and VCL811–1066, both of which arrest talin association. Thus, VCL binding talin, but not Arp2/3, is critical for osteoclast function, and its selective inhibition retards physiological bone loss.